AN2 Therapeutics, Inc. ANTX
Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026
AN2 Therapeutics, Inc. (ANTX) is a healthcare company listed in the US with a market value of about $173M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -48%.
About AN2 Therapeutics
AN2 Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2022. It was profitable in 0 of the last 5 years in our data. Its share count rose by 97% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | -$35M | -$51M | -$65M | -$41M | -$22M |
| Free cash flow | — | — | — | — | — |
| EPS (diluted) | $-1.16 | $-1.72 | $-2.74 | $-2.79 | $-10.64 |
| Net margin | — | — | — | — | — |
| ROIC | -56.7% | -54.8% | -44.1% | -35.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does AN2 Therapeutics pay a dividend?
Not currently.
Is AN2 Therapeutics a good stock to buy?
We do not give buy or sell advice. AN2 Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.